Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature (ELEGANCE)
Boston Scientific Corporation
5,000 participants
Mar 29, 2021
OBSERVATIONAL
Conditions
Summary
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Eligibility
Inclusion Criteria3
- Patients 18 years and older
- Written informed consent (patient data release-form)
- Use of any commercially available Boston Scientific drug-eluting device marketed for treatment of lesions in the peripheral vasculature and specified in the Registry Enrollment Guide
Exclusion Criteria1
- Life expectancy of \<1 year
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
Locations(79)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04674969